Background. Few interventions have been successful in improving gait dysfunction in patients with multiple sclerosis (MS). Rhythmic auditory stimulation (RAS) has demonstrated positive results on gait performance in other neurologically impaired populations. Objective. To measure the effects of RAS on quantitative walking parameters in ambulatory patients with MS. Methods. Ten MS patients with gait disturbance were randomly assigned to receive RAS versus no intervention for 2 weeks. All participants received RAS for another 2 weeks. Between weekly clinic visits, they were provided with MP3 players containing songs whose tempo was 10% above the participant's spontaneous cadence and were instructed to walk to the music 20 minutes daily. Quantitative gait parameters were measured using the GAITRite system. Results. A statistically significant decrease between groups was found for change in double-support time (left, P = .0176; right, P = .0247), whereas trends with medium to high effect sizes were found for other gait parameters, including walking speed. A pooled within-group analysis showed significant improvement of cadence, stride length, step length, velocity, and normalized velocity after 1 week of treatment. Satisfaction level with RAS was high. Conclusions. These results in a convenience sample of MS patients demonstrate the feasibility and safety of RAS when used at home and suggest a potential benefit on gait parameters.
Introduction
Multiple sclerosis (MS) frequently affects ambulation. 1 In a recently published survey of 166 individuals with MS, 2 lowerlimb functioning was identified as the most important bodily function, outscoring both vision and cognition. These observations underscore the need to develop interventions that can stabilize or improve walking. First-line disease-modifying therapies may slow down the accumulation of MS-related disability over time but generally do not improve existing gait disturbance. A variety of interventions have been studied that revealed at best modest benefits on walking performance in MS patients, including biofeedback, 3 physical therapy, [4] [5] [6] [7] central conduction modulators such as 4-aminopyridine, 8 disease management with high-dose cyclophosphamide, 9 and symptomatic therapies for spasticity. 10 The fact that MS is a neurodegenerative disease that involves different areas of the central nervous system in different people helps explain why no one intervention for gait disturbances works consistently across patients.
Timing for gait is processed in many different areas of the central nervous system. 11, 12 When an area linked with auditory motor regulation is damaged, such as the cerebellum, rhythmic motor entrainment can still occur. 12 Rhythm has been shown to activate different motor areas of the central nervous system, including the cortex, 11 cerebellum, 11, 12 and spinal tract. 11, 13 Rhythmic auditory stimulation (RAS) is a neurological music therapy technique developed to use rhythm and timing cues to improve the intrinsic rhythmic movements of gait. 11 RAS works through several different processes, including rhythmic entrainment and limit cycle entrainment. 12 It has produced significant improvements of gait abnormalities in other neurological disorders, including Parkinson's disease, stroke, traumatic brain injury, and Huntington's disease, but we found no published studies of RAS in patients with MS.
Walking limitations in MS are often related to spastic paraparesis, with asymmetrical lower-extremity impairments. Gait abnormalities frequently reported in MS include decreased walking speed, decreased step and stride length, and increased double-support time. 14, 15 In Parkinson's disease and stroke, 16, 17 RAS has led to significant improvements in stride length, step length, cadence, and walking velocity [16] [17] [18] [19] [20] [21] [22] as well as significant improvements in synchronization and decreased variability during EMG studies. 22, 23 The purpose of our study was to determine if RAS-mediated walking exercise leads to improvements in stride length, walking speed, and other gait parameters in ambulatory patients with MS at various levels of disability. Because walking exercise with RAS has never been reported in MS patients, we paid particular attention to the feasibility and safety of our intervention. Research in other neurological conditions has shown that 20 to 30 minutes per day of a home-based walking program (HBWP) with RAS is acceptable and beneficial. 19, [21] [22] [23] To explore the potential impact of a HBWP with RAS on walking performance in MS patients, we designed a randomized controlled pilot study, comparing walking exercise to music, with an embedded beat that was 10% above the participant's spontaneous cadence, with no intervention. We hypothesized that the HBWP with RAS would produce significant improvements in stride length, walking speed, and other quantitative gait parameters and would be acceptable and safe in ambulatory MS patients at various levels of disability.
Materials and Methods

Participant Recruitment
The study was approved by our institutional review board. Potential candidates were identified by their treating clinician among patients followed at our MS center and were contacted by phone using an IRB-approved script. Patients who expressed interest were mailed a letter of introduction to the study as well as a copy of the informed consent form. Patients were considered for enrollment if they met the following inclusion criteria: 18 years of age or older, diagnosis of MS documented in the medical records, able to walk at least 100 feet without physical assistance (use of assistive devices such as cane, crutch, or walker was allowed), and able to walk 25 feet in 8 to 60 s. Exclusion criteria were as follows: treatment for an MS exacerbation in the previous 30 days, severe comorbidity that precluded participation in the study per principal investigator's judgment (eg, severe cardiac or respiratory failure), and severe cognitive deficits precluding informed consent or preventing the participant from following study procedures. Written informed consent was obtained. Each participant received stipends spread out over the course of the study visits to cover their expenses. MP3 players and headphones were provided, and participants were asked to return the MP3 player at the end of the study.
Gait Parameters
The GAITRite system (CIR Systems Inc, Havertown, PA) is a portable, computerized device designed to analyze temporal and spatial gait parameters. The system consists of a mat (approximately 30 feet long) with embedded sensors, linked to a computer with a proprietary software. Several studies have reported the reliability and validity [24] [25] [26] [27] of the GAITRite in various populations, including healthy young and elderly individuals 28 as well as patients with knee replacement, 29 Parkinson's disease, 27 and MS. 14 Patients with MS demonstrated decreased step length, cadence, functional ambulation performance score, and walking velocity when evaluated against with preestablished norms. 14 The GAITRite system has also been used to assess changes in gait parameters with RAS in patients with Parkinson's disease. 18 We collected the following variables from the GAITRite system: double-support time (percentage), step length, cadence, velocity, stride length, normalized velocity (the speed of each leg based on leg length, stride length, and velocity), and the functional ambulation performance score (a score derived from a number of ambulation parameters, including cadence, stride length, and normalized velocity).
The Timed 25-Foot Walk Test (T25FW) is a widely used walking performance test in MS clinical trials and routine care. The participant is instructed to walk safely at maximal speed for 25 feet. We chose the T25FW as an efficacy variable because it has been extensively validated in MS.
Other Descriptive Variables and Outcome Measures
The following information was collected: demographics (age, gender, height, weight, leg length), disease characteristics (date of symptom onset, date of diagnosis, clinical course at onset, current clinical course), and active comorbidities.
Outcome measures included the following:
1. Spasticity was measured using the Modified Ashworth Scale (MAS), an ordinal scale rating resistance to passive movement from 0 = no resistance to 4 = contracture, and the Spasm Frequency Scale, an ordinal scale with scores between 0 = no spasm and 4 = more than 10 spontaneous spasms per hour. Spasticity was assessed as an explanatory variable because improvements in gait performance could be mediated by improvements in spasticity. 2. Muscle strength was measured by upper-and lowerextremity manual muscle testing (MMT) using the Medical Research Council Ordinal Scale between 0 = no muscle contraction and 5 = normal strength.
Muscle strength was assessed as an explanatory variable because improvements in gait performance could be mediated by improvements in strength. 3. Pain was measured by the Numeric Pain Rating Scale with scores between 0 and 10. Pain was assessed as a safety variable because walking exercise may lead to increased musculoskeletal and neuropathic pain. 4. Ambulation disability was measured by the Ambulation Index (AI), which is an ordinal scale rating walking (and transfer) performance between 0 = no gait abnormality and 9 = restricted to wheelchair, dependent for transfers. Scoring of the AI is based on the presence of gait disturbance, the need for assistive devices, and the time to walk 25 feet.
MS-related disability was measured by the Patient-
Determined Disease Steps (PDDS), an ordinal scale rating the severity of self-reported disability caused by MS, with scores between 0 (normal) and 8 (bedridden). We used the PDDS to verify the stability of overall MS-related disability throughout the study because new disease activity may affect our results. 6. Overall treatment efficacy was measured by the Subject Global Impression (SGI) of change and the Clinician Global Impression (CGI) of change. 7. Satisfaction with treatment: at the last visit, all participants were asked to complete a satisfaction survey specifically designed for this study, which included 9 statements covering a variety of aspects of both the RAS treatment and the HBWP. Each statement was scored on a Likert scale from 1 = strongly disagree to 6 = strongly agree.
Study Design
The total study duration was 6 weeks, with an initial 2-week randomized controlled parallel arm design; then, all participants received treatment during the following 2 weeks. Evaluations were performed at baseline (Visit 1 = V1), then at the end of week 1 (V2), week 2 (V3), and week 3 (V4). The participants continued to participate in the HBWP during the fourth week, but no visit was scheduled at the end of week 4. All participants returned for a final evaluation 2 weeks after the end of treatment (V5). Participants were randomly assigned to the control group or the treatment group. Those in the treatment group participated in the HBWP throughout the study period. Those in the control group did not participate in the HBWP during the first 2 weeks but participated in the HBWP for the remainder of the study period. Each participant received an MP3 player with the same 8 songs. These were instrumental songs electronically produced specifically for RAS training and covering different genres such as classical, folk, and jazz and had a beat embedded within the music. Whereas some investigators 18 have provided the auditory cue with a metronome, most of the studies to date demonstrating significant findings have used a musical stimulus (autoharp, piano, recorded music with embedded beat). 16, 17, [19] [20] [21] [22] [23] Each song was replicated in 15 cadences (50-120 bpm in increments of 5 bpm), which the music therapist kept catalogued on a laptop computer. Each week, the music therapist ensured that the appropriate set of songs was in each participant's MP3 player based on the participant's spontaneous baseline cadence + 10% for that particular visit. Those in the treatment group received their MP3 player with headphones the first week and were instructed to walk to the music 20 minutes per day every day for the following 4 weeks. Those in the control group received their MP3 players with headphones the third week and were given the same instructions but for 2 weeks only. The participants were instructed to walk safely and comfortably and were allowed to break down the 20 minutes into smaller increments if walking continuously for 20 minutes was not feasible. All participants were asked to keep a daily journal documenting if they walked and for how long. Because no visit was scheduled following the fourth week, participants were given the date they were to stop participating in the HBWP and instructed to mark in their journals that they had done so.
Testing was performed in the following order during weekly visits: all questionnaires were administered first; muscle strength, spasticity, and pain were assessed before any gait testing to avoid any changes related to walking; then, all participants performed 2 walks on the GAITRite followed by T25FW testing on the regular floor (to follow standard administration instructions) and then 2 additional walks on the GAITRite. Therefore, walks were registered before and after a test at maximal walking speed, which is expected to cause fatigue, then averaged. During the treatment period, participants also performed 2 walks with RAS at their spontaneous walking cadence and 2 walks with RAS 10% above their spontaneous cadence. RAS was provided by the study music therapist, playing chord progressions on an Oscar-Schmidt Autoharp. An electronic metronome with headphones was used to ensure the reliability of the cadence. The rationale for these additional walks was to provide RAS training and to ensure that the participants were able to walk safely to RAS. Participants were able to use their usual walking aid (eg, cane, walker) and were asked to use it consistently throughout the study. To better understand the data registered by the GAITRite, participants were videotaped while walking.
Statistical Analysis
Differences between the treatment and the control group at V1 were assessed using the independent sample t test (age, BMI, disease duration, number of comorbidities, and gait parameters), the Wilcoxon 2-sample test (MMT, MAS, and AI), and Fisher's exact test (gender and disease course). We did not control for repeated measures in this exploratory pilot study.
The planned efficacy analyses were conducted on the first 2 weeks of the study. Mean changes from visit 1 to visit 3 were compared between treatment and control groups, using a 1-tailed t test for independent samples. In addition, withingroup comparisons between V1 and V3 were conducted in each group using a paired t test. Finally, descriptive statistics were generated for SGI, CGI, and satisfaction questionnaire items.
All significance tests were 2-tailed, except when looking at change from visit 1 to visit 3. Because the expectation was that RAS would produce positive effects through the duration of the study, tests to evaluate change were 1-tailed. The significance level was set at P < .05. Because this was a pilot study looking for trends, there was no correction for multiple comparisons. All analyses were conducted with the SAS v9.2 (SAS Inc, Cary, NC) software.
Results
Ten participants were recruited following the process described above.
Between-Group Comparisons at Baseline
No significant differences in demographic and medical characteristics or gait parameters were observed between the treatment and control groups at V1, although gait parameters were slightly better in the treatment group overall (Table 1 ).
Outcome at the End of the Randomized Controlled Period
Gait parameters. The treatment group exhibited a significantly greater improvement in percentage double-support time on the left (P = .0176) and right sides (P = .0247). There were no other significant differences in V3-V1 mean change scores between the treatment and the control groups. However, most effect sizes (mean difference divided by the pooled standard deviation) for the difference in mean change scores were above 0.3 (moderate effect size), and differences in mean change scores were favorable to the treatment group (Table 2 ).
In addition, there was a statistically significant improvement in double-support time for the left leg between V1 and V3 (P = .0410) in the treatment group. Although the differences between V1 and V3 for other gait parameters did not reach statistical significance in either group, no negative mean changes occurred in the treatment group, whereas changes were more erratic in the control group (Figure 1) .
Other outcomes. There were no statistically significant changes in MAS, MMT, Numeric Pain Rating Scale, AI, or PDDS scores (between-group and within-group comparisons). A total of 9 out of 10 participants reported a positive change on the SGI at the end of the study. Four out of 10 participants were found to have a positive change on the CGI (3 of those were in the treatment group).
Within-Group Comparison on All Participants After 1 Week of HBWP
Because most within-group comparisons showed moderate to large effect sizes without statistical significance (suggesting that our study was underpowered for most outcomes), we conducted a post hoc analysis. We pooled data from all participants and performed a within-group comparison between the visit immediately preceding treatment (V1 for the treatment group and V3 for the control group) and the end of the first week of treatment (V2 and V4), using a paired t test. Because the study design did not include a visit at the end of the second week of treatment for the control group, only 1 week of comparative data were available for both groups.
There was a statistically significant improvement of most gait parameters, and large effect sizes were observed for the majority of parameters (Table 3 ).
Acceptability and Safety of the HBWP With RAS
No participant discontinued participation in the study, and all reported full compliance with the HBWP. No MS exacerbations were reported during the study. Two treatment participants reported urinary tract infections during the study, possibly providing a negative impact on their overall data. No falls were reported while walking to music, and 1 fall was reported during the entire duration of the study. Each participant was asked to rate their pain prior to and immediately following RAS training during each visit; 8 participants reported either no pain, no change in their pain, or a decrease in their pain. One participant reported increased pain in 3 out of 4 visits, and another in 1 out of 4 visits. Results of the satisfaction survey at the end of the study show a high satisfaction level.
Discussion
To our knowledge, this is the first study to use RAS in MS treatment. We conducted a 4-week HBWP using RAS in 10 participants with MS and significant walking limitations (3 used a cane, 1 used 2 walking sticks, and 6 used a rollator). The program was well accepted and well tolerated ( Table  4 ) and did not result in significant safety concerns such as increased falls. Although publications on the effect of RAS and exercise on gait have reported safety parameters in their baseline demographics, such as number of falls per month, and have discussed the potential for increased walking safety based on their results, these articles do not mention monitoring of specific safety parameters, such as number of falls or pain, during the study. 17, [19] [20] [21] [22] [23] We acknowledge methodological limitations to this study. The sample size was small, and our patients were not representative of the entire spectrum of those with disability from MS. The overall treatment period was short and was even shorter for the controlled portion of the study. Because the control group received no intervention during the first 2 weeks, a placebo effect cannot be excluded. If the patient's spontaneous cadence increased over time, the training cadence was accordingly increased. Therefore, the musical stimulus was not always stable over time within and between patients: for example, 80% of participants had their music increased following their first week of the HBW, and 60% had a change, increased or decreased, after the second week. The evaluators were not blinded to the participants' group assignments, potentially introducing a bias. However, gait parameters were quantitatively assessed using an automated system and did not rely on the evaluator's subjective assessment. The participants could not be blinded because of the nature of the treatment. Assessment of participant adherence to the exercise regimen relied solely on self-report. Our planned efficacy analysis showed a statistically significant treatment effect after the 2-week randomized controlled period for percentage double-support time. A healthy person spends, on average, approximately 20% of their gait cycle in double support and the remaining 80% in single support (divided by each leg). At baseline, our treatment group spent an average 35% in double support, and our control group 41%. Prolonged double-support time is linked with a decrease in walking speed 30 and gait instability. 15 The decrease in double-support time, as demonstrated in this study, indicates an increase in gait stability.
Effect sizes over the 2-week controlled period, both for the difference in change between groups and for within-group changes, were moderate or large for most gait parameters. Also, average gait parameter change scores were more consistently positive in the treatment group, and global impression of change scores favored the treatment group, both from the clinician's and participants' perspectives. Furthermore, an analysis of within-group change on data pooled from all participants after 1 week of treatment showed statistically significant improvement and large effect sizes for most gait parameters. Altogether, these findings suggest that the HBWP using RAS was effective in improving walking performance and that an adequately powered study could detect a significant treatment effect in a greater number of gait parameters.
Many RAS studies have looked at stride length and velocity as their primary outcome measures. [16] [17] [18] [19] [20] [21] [22] [23] Two studies, one with Parkinson's disease 17 and one with stroke patients, 22 that used a HBWP of 20 to 30 minutes per day over a 3-week period showed improvements in velocity of 11.1 m/min and 20.4 m/ min, and improvements in stride length of 11.1 cm and 35 cm, respectively. Although it did not reach statistical significance during the control phase, the current study yielded improvements of 6.2 m/min (velocity) and 5.3 cm (stride length). The smaller gains in this study could be explained by the fact that we reported on only 5 participants, who were more disabled at baseline compared with those in other studies (all our participants walked with assistive devices). The gait improvements in this study went beyond velocity and stride length because 80% of the participants demonstrated positive changes in 9 of 11 gait measurements.
Although the mechanisms for change through RAS are not completely understood, it appears that by providing a structural template, in this case the steady cadence, the natural rhythmic movements of walking can be positively modified through entrainment processes. Both Hausdorff et al 16 and Thaut and colleagues 11, 20 extrapolate on this idea by positing that RAS must influence the brain's oscillators and timekeeper functions that regulate gait as evidenced by positive carryover effects after the musical stimulus is removed. In our study, assessment of stride length at the last visit (V5), after 2 weeks off RAS, showed sustained improvement in the treatment group (4 weeks of RAS) but not in the control group (2 weeks of RAS). In turn, the increased exercise level from participation in a RAS-focused HBWP may have a positive impact on other consequences of MS, particularly fatigue. 31, 32 Another factor that may contribute to the positive effects of this study is the increased motivation provided by the music. Adherence to home exercise regimens is decreased in patients with MS. In addition to its intrinsic effects on gait, RAS may improve the adherence to walking exercise by making it more enjoyable and by increasing the patients' sense of control. Music can also act as a distracter from discomfort when doing any type of physical exercise. Indeed, most of our participants indicated that they would continue the HBWP beyond the study period (Table 4) .
Our results need to be replicated with a larger number of participants, covering a larger spectrum of walking disability, using a randomized, controlled, single-blind design. Doublesupport time appears to be a sensitive and meaningful potential primary outcome. Using the patient's favorite music with an embedded beat may enhance motivation, whereas keeping the cadence stable after an initial increase would provide a more consistent stimulus. The transferability of improvements seen in the gait lab into daily life could be evaluated with validated patient-reported outcome measures (such as the MS Walking Scale-12) and with objective tools such as oscillometers. Furthermore, the efficacy of RAS-based protocols should be tested against exercise without RAS and against listening to music without walking exercise. Finally, safety issues such as the frequency of falls and potential for musculoskeletal pain because of the increased activity should be kept in mind and monitored.
Conclusions
Our findings suggest that an RAS-based walking program has the potential to be a safe and effective intervention for gait disturbance in patients with MS. This simple and low-cost intervention needs to be studied in larger samples of MS patients who walk slowly in a randomized assessorblinded trial design to determine whether walking speed and related physical functioning in the community can be improved. Based on our preliminary effect sizes, this trial may require no more than 40 to 50 participants per arm. 
